Key result
Lanthanum carbonate showed no significant difference compared to calcium carbonate in the progression of cardiac valvular calcification at 18 months.
Why the study?
Although mineral metabolism disorder influences cardiac valvular calcification, few studies have examined the effects of non-calcium-containing versus calcium-containing phosphate binders on cardiac valvular calcification in maintenance hemodialysis patients.
Does lanthanum carbonate prevent the progression of cardiac valvular calcification compared to calcium carbonate in patients initiating maintenance hemodialysis?
RCT (n=50)
Does lanthanum carbonate prevent the progression of cardiac valvular calcification compared to calcium carbonate in patients initiating maintenance hemodialysis?
There is no significant difference between lanthanum carbonate and calcium carbonate in preventing the progression of cardiac valvular calcification in patients initiating hemodialysis.
LC does not slow CVC progression versus CC in incident hemodialysis; confirms similar effects of calcium- and non-calcium-based binders on valvular calcification.
BACKGROUND: Although mineral metabolism disorder influences cardiac valvular calcification (CVC), few previous studies have examined the effects of non-calcium-containing and calcium-containing phosphate binders on CVC in maintenance hemodialysis patients. The aim of the present study was to compare the effects of lanthanum carbonate (LC) with calcium carbonate (CC) on the progression of CVC in patients who initiated maintenance hemodialysis and to investigate clinical factors related to CVC. METHODS: The current study included 50 subjects (mean age 65 years, 72% males) from our previous randomized controlled trial (LC group, N = 24; CC group, N = 26). CVC was evaluated as CVC score (CVCS) using echocardiography at baseline and 18 months after initiation of hemodialysis. We compared CVCS and the changes between the two groups. We also analyzed the associations between CVCS and any other clinical factors including arterial plaque score (PS) and serum phosphorus levels. RESULTS: Baseline characteristics of study participants including CVCS were almost comparable between the two groups. At 18 months, there were no significant differences in mineral metabolic markers or CVCS between the two groups, and CVCS were significantly correlated with PS (r = 0.39, p < 0.01). Furthermore, changes in CVCS were significantly correlated with average phosphorus levels (r = 0.36, p < 0.05), which were significantly higher in high serum phosphorus and high PS group compared to low serum phosphorus and low PS group (p < 0.05). CONCLUSIONS: In the present study, there were no significant differences between LC and CC with regard to progression of CVC. However, serum phosphorus levels and arterial plaque seem to be important for the progression and formation of CVC in hemodialysis patients.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (2020) conducted an RCT in Maintenance hemodialysis (n=50). Lanthanum carbonate vs. Calcium carbonate was evaluated on Progression of cardiac valvular calcification (CVC score). Lanthanum carbonate showed no significant difference compared to calcium carbonate in the progression of cardiac valvular calcification at 18 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: